Good day, everyone, and welcome to the Syndax Second Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.

Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's second quarter 2024 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; Steve Closter, Chief Commercial Officer; and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer. This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on Slide 2. Before we begin, I would like to remind you that any statements made during the call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in the company's most recent quarterly reports on Form 10-Q as well as other reports filed with the SEC. Any forward-looking statements made represent our views as of today, August 1st, 2024, only. A replay of this call will be available on the company's website following its completion. With that, I'm pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax.

Thank you, Sharon. Good afternoon, everyone, and thank you for joining us today. Starting with Slide 3, this is a very exciting year for Syndax. We stand on the cusp of becoming a commercial stage company with the anticipated upcoming FDA approvals of Revumenib and Axatilimab, new first-in-class treatments for diseases with high unmet medical needs. I'm pleased to report that we have achieved several clinical milestones in the second quarter that support our strategic priorities. In June, we presented updated positive Revumenib combination data from the BEAT AML and AUGMENT-102 trials at the European Hematology Association, or EHA Congress. These data, which Neil will review shortly, continue to support Revumenib's potential to enhance current standard of care agents. At EHA, we also presented additional positive data from the AGAVE-201 pivotal trial evaluating Axatilimab in patients with refractory chronic graft versus host disease, or GVHD. Reinforcing the previous organ response data that we had shared, this latest data set shows that responses were noted in all fibrosis-dominant organs that had clinical activity supported by clinician-reported and patient-reported changes in organ-specific symptoms such as improvements in swallowing, shortness of breath, skin and joints, and sclerotic skin. Looking ahead, we are on track for a historic year with the anticipated FDA approval of Revumenib and Axatilimab coming soon with Axatilimab, our anti-CSF-1 antibody for patients with chronic GVHD. We have a PDUFA action date of August 28th, 2024, and anticipate launching in the fourth quarter of this year with our partner Incyte. With Revumenib, our menin inhibitor, being reviewed by the FDA for patients with relapse or refractory KMT2A-rearranged acute leukemias, we have a PDUFA action date of December 26, 2024. As we announced earlier this week, the FDA recently extended the PDUFA action date for Revumenib NDA from September 26 to December 26, 2024, a standard three-month extension to allow for additional time to conduct a full review of supplemental information we provided in response to their requests. Importantly, we are confident that the information we have provided supports approval and continues to demonstrate the meaningful benefit Revumenib brings to patients. We look forward to continuing to closely engage with the FDA as they complete the review under the Real-Time Oncology Review Program, or RTOR, and we stand ready to launch Revumenib with strength as soon as we receive the anticipated approval. Later in the call, Steve will provide some additional color on our preparations for these two anticipated launches. We also have several other meaningful milestones approaching, such as the anticipated readout of pivotal top-line Revumenib data in relapsed or refractory and NPM1 AML in the fourth quarter, which could serve as the basis for a supplemental NDA filing in the first half of 2025. Additionally, we expect to make further progress advancing our clinical trials of Revumenib and Axatilimab that are underway or planned to initiate in the coming months. Positive results could support the future use of these agents in combination with standard-of-care medicines earlier in a patient's treatment and thereby expand their utility significantly. We are in a strong financial position with $455 million in cash as of June 30th that we expect will provide sufficient capital through 2026. Our current balance sheet not only supports our planned commercial launches and clinical trials but also sets us up to expand beyond our first registration indications and to pursue early-stage business development opportunities. I will now ask Neil to review some of our recent data presentations and pipeline. Neil?

Thanks, Michael. Turning to Slide 4, in Revumenib, we have a robust clinical development strategy underway that will support the use of Revumenib in KMT2A-rearranged and mutant NPM1 acute leukemias across the treatment paradigm. The development plan extends beyond the initial relapsed or refractory indications with trials of Revumenib in combination with standards of care that potentially support use of the frontline, relapse, refractory, and post-transplant maintenance settings. On the next two slides, I will briefly review the data recently presented at EHA from the two combination trials that you see listed, BEAT AML and AUGMENT-102. On Slide 5, at EHA in June, we and our collaborators at the Leukemia Lymphoma Society presented updated data from the BEAT AML trial of Revumenib in combination with venetoclax, azacitidine, or Ven/Aza in patients newly diagnosed with mutant NPM1 or KMT2A-rearranged AML. This updated data set, with a cut-off of the 1st of May 2024, includes 24 efficacy evaluable patients, 96% of patients had a composite complete response for CRc, and 92% had no residual disease and were therefore MRD-negative. As in all the combination trials conducted so far, two doses of Revumenib are being investigated, 113 milligrams and 163 milligrams administered every 12 hours. The dose-limiting toxicity or DLT window for each was cleared last year on this trial, and both cohorts are currently being expanded in order to identify the dose for Phase 3 development. The combination is well tolerated, and the safety profile reported at EHA is consistent with what has been previously reported. Of note, the rates of adverse events associated with the combination of Revumenib with Ven/Aza observed in the study are consistent with data for Ven/Aza from historical controls. For example, the addition of Revumenib to the doublet does not appear to exacerbate the modest toxicity associated with Ven/Aza alone. Additionally, the BEAT AML investigators concluded that the data suggests that adjusting the dose of venetoclax while maintaining the dose of Revumenib may be the most logical strategy for future development. As we previously communicated, we intend to initiate a pivotal trial with this triplet combination in newly diagnosed patients by year-end. Turning to Slide 6, at EHA, we also presented updated data from the AUGMENT-102 trial of Revumenib in combination with fludarabine/cytarabine or FLA in a predominantly pediatric population with relapsed refractory mutant NPM1, NUP98-rearranged, or KMT2A-rearranged AML. As of the date of cutoff of the 15th of January 2024, 27 patients received FLA plus Revumenib at 113 milligrams or 163 milligrams. Patients included in the trial were heavily pretreated, with a median of three prior lines of therapy; 67% had prior FLA-containing regimens, and 52% of patients achieved composite complete remission or CRc. The MRD-negative rate among CRc patients was 71%. Furthermore, seven patients, or 50% of responders, proceeded to transplant once they had entered remission. As with the Ven/Aza triplet we just discussed, Revumenib does not appear to alter the tolerability profile of the standard of care regimen. These two updated data sets presented at EHA provide further support for combining Revumenib with different standards of care in the newly diagnosed as well as relapsed or refractory settings. Turning to Slide 7, in March, we completed enrollment in the pivotal cohort of the AUGMENT-101 trial with the enrollment of 64 adults and up to 20 pediatric relapsed refractory NPM1 mutant AML patients. We are on track to report data in the fourth quarter. On this slide, you can see the results from 14 mutant NPM1 patients in the Phase 1 portion of AUGMENT-101, which showed that 50% of patients achieved a response and 36% achieved a complete remission or CR, with partial hematological recovery. Notably, all patients with a CRh were MRD negative, consistent with the KMT2A population. Revumenib also enabled patients in remission to proceed to transplant with durable responses, despite many of the patients having failed prior venetoclax therapy and stem cell transplant. These data also indicate that Revumenib is well tolerated in patients with mutant NPM1 with an overall safety profile that is consistent with what has been previously reported in the KMT2A-rearranged population. Before I hand over to Steve, I'd like to provide a quick overview on Slide 8 of the preparations we've made on the medical side of the organization to support the upcoming anticipated launches. We've built a highly experienced Medical Affairs team that is driving deep scientific engagement and robust evidence generation. As you've seen from our participation in ASH and EHA, as well as various papers in top-tier journals such as Nature, we have an ambitious conference and publication plan underway to increase awareness of the compelling data from our two agents. We also continue to prepare for future NCCN guidelines submissions for Revumenib that we anticipate will include the prescribing information as well as peer-reviewed publications and congress presentations. Of note, once the top-line data in mutant NPM1 AML are available, we plan to publish as soon as it's feasible to support potential guideline inclusion following the approval of Revumenib in KMT2A. Additionally, we have a team of seasoned medical science liaisons in the field. They've made tremendous progress driving scientific exchange with physicians at major centers of excellence across the country. We've also built a health economics and real-world evidence team focused on supporting the value of our portfolio, and we continue to increase engagement with patient advocacy groups. With that, I'll now turn over to Steve to talk about our commercial launch plans and the market opportunities. Steve?

Thank you, Neil, and thanks to everyone for joining us today. I really appreciate it. It's a pleasure to be with you to talk about the extensive preparations we're making to position Syndax as the leading commercial stage organization serving patients and healthcare providers. We are well prepared to execute on the exciting opportunities in front of us. Turning to Revumenib preparations on Slide 8, our goal is a strong launch, and we are ready to hit the ground running with Revumenib as soon as we receive the anticipated approval from the FDA. We've hired and trained a sales team with extensive experience and pre-existing relationships in the hematology oncology space and a demonstrated track record of success. This team is in the field right now profiling accounts and understanding the patient treatment journey so we can meet the needs of the different stakeholders involved in their care. This robust pre-launch preparation will let us rapidly begin meeting patient needs upon the anticipated approval. Our customer-facing team has an average of 22 years of experience, primarily in hematology and oncology, with an average of six product launches each. With an efficient field force footprint in the range of 30 to 50 individuals, we believe that we can effectively reach the relevant academic and community-based centers and meet the needs of physicians and patients. We plan to call on approximately 2,000 centers, with roughly 200 of those accounts representing more than two-thirds of the opportunity, enabling a concentrated effort. With our plan, we believe we should reach centers where 98% or more of potential relapse-refractory KMT2Ar patients receive treatment. Now, another important thing we've done in preparation for the launch is develop advanced data mining capabilities to appropriately identify patients in need. Because these are high-risk patients that require rapid identification of the treatment options, we've developed capabilities that will help us initiate very targeted physician engagement based on where our tools indicate there are appropriate patients. Now, with respect to market access, we've built an accomplished team with extensive experience working with payers and other trade partners to facilitate access to new products. Together with the Medical Affairs team, our payers field team continues their pre-approval information exchange work with payers, and we're on track to reach plans covering more than 90% of all covered lives, both commercial and Part D, prior to the anticipated approval. Payers tell us that they recognize the unmet needs and appreciate the value that Revumenib provides. We believe plans will make their formulary decisions within six months to twelve months of approval, and we'll work with them to expedite the review when possible. Importantly, given the urgent patient need, we expect that plans will provide patients access to the product at launch through the medical exception process. To support providers and patients, we've partnered with leading best-in-class specialty pharmacies who are well recognized for their ability to help providers and patients navigate access to new oncology medicines. Through a network of specialty pharmacies and specialty distributors, we're prepared to have product and channel available very quickly, right after we receive approval. We're also ready to launch a dedicated patient support program that will provide a level of support on par with what you see from leading oncology companies. Turning to Slide 9 and the market opportunity, KMT2Ar and NPM1 acute leukemias represent up to 40% of all AML patients. There are no FDA-approved targeted therapies for this population. We believe relapse or refractory KMT2Ar acute leukemia alone represents a total addressable market opportunity of approximately $750 million in the U.S. The annual incidence of KMT2Ar acute leukemia is about 2,600 patients, with the majority of these patients, about 2,000, experiencing relapsed or refractory disease. We estimate a median duration of therapy across the treated population of approximately nine months, and we believe the clinical data supports pricing competitively to other targeted therapies in AML, such as FLT3 or IDH inhibitors. Physicians we've spoken with indicate an eagerness to prescribe Revumenib early during an eligible patient's treatment journey, to bring more patients to transplant, and then extend responses by continuing with Revumenib monotherapy following transplant engraftment. We expect that our first mover advantage and the early experience physicians will gain treating patients with Revumenib will be vitally important to the long-term success of our brands. Our significant market share is likely to extend meaningfully beyond KMT2Ar, especially as we will be the first to deliver meaningful, pivotal data in other indications such as NPM1 AML. We estimate that the two distinct market segments in acute leukemias, KMT2Ar and NPM1, equal a combined accessible population of 5,000 to 6,500 patients in the relapse or refractory setting and an addressable market opportunity that approaches $2 billion in the U.S. During the various meetings that I've had the chance to participate in with clinicians, from advisory boards to field visits and more, I've seen tremendous excitement and support for Revumenib, creating a momentum that I look forward to building on through our commitment to delivering an absolute best-in-class experience for healthcare providers and patients. Moving to Axatilimab on Slide 10, the anticipated commercialization of Axatilimab will be led by the Incyte team and will benefit from the deep experience and longstanding relationships that they've established through their work building the GVHD market with Jakafi. We'll provide 30% of the sales effort, leveraging our own field force that we anticipate will carry two products with highly overlapping call points, paving the way for a successful launch. Incyte is continuing to drive engagement with payers and raise awareness of the distinct pathway that Axatilimab targets and the compelling outcomes observed in the AGAVE-201 trial, which we recently detailed at the 2023 ASH Congress. Turning to Slide 11, we estimate there are approximately 17,000 patients on treatment for chronic GVHD at any one time, the majority of whom are refractory and cycle through therapies for better symptom control as their disease progresses. We believe there are approximately 6,500 patients progressing to later lines of treatment after two previous lines of treatment, which would be our target population for our first indication and represents an attractive initial opportunity. For instance, in the three years since the launch of Rezurock, another drug with a third-line indication, net sales continue to grow and they are annualizing at nearly $500 million. We estimate that the total addressable market for third-line treatment in the U.S. is between $1.5 billion to $2 billion, which assumes that patients will remain on therapy for over 12 months and assuming Axatilimab is priced at a premium to approved agents for chronic GVHD based on its product profile and Part D reimbursement. Beyond the third-line setting, we plan to study Axatilimab in earlier line settings for chronic GVHD and other diseases where we believe its anti-fibrotic and anti-inflammatory mechanism is relevant, such as IPF, which represents a large opportunity. I'll now turn the call over to Keith to review our financial results.

Thank you, Steve. Turning to Slide 12, as Michael mentioned earlier, the $455 million in cash equivalents and short and long-term investments on our balance sheet as of June 30th is expected to provide runway through 2026. Our financial strength allows us to fund the anticipated commercialization of two drugs and appropriately invest to continue to realize the value of our pipeline. Turning to the income statement, operating expenses in the second quarter were $77.7 million and included $48.7 million of research and development expense and $29.1 million of selling, general, and administrative expense. I'd like to provide financial guidance for the third quarter and full year 2024. For the third quarter, the company expects research and development expense to be $70 million to $75 million and total operating expenses to be $105 million to $110 million. For the full year of 2024, there is no change to the existing guidance and the company expects research and development expenses to be $240 million to $260 million and total operating expenses to be between $355 million to $375 million. Please note that the guidance range for operating expenses for the full year includes an estimated $43 million of non-cash stock compensation expense and that research and development expense guidance includes any milestones owed to our partners on potential drug approvals. Ahead of the upcoming launch of Axatilimab, I want to briefly review how we will recognize revenue for that partner and product. Slide 13 provides an illustrative example of accounting for sales of Axatilimab and is not intended to provide any margin or any other guidance. We will record 50% of the commercial profit defined as net product revenue minus the cost of sales and commercial expenses. During the period where there is net commercial profit for Axatilimab, as in the top example of the slide, our 50% share of the net profit will be recognized under P&L as collaboration revenue. During the period where there is a net commercial loss for Axatilimab, as in the example on the bottom of the slide, our 50% share of the net commercial loss would be included in operating expenses designated as a separate line item called share of collaboration loss. The milestone revenue from various global commercial and regulatory milestones that we receive from Incyte will be recorded as milestone revenue on our income statement. As a reminder, research and development expenses under our partnership, including regulatory and CMC expenses, are shared 55/45 in the U.S., and our 45% share is included in the income statement as part of our R&D expense. Outside of the United States, Incyte is responsible for 100% of the development and regulatory expenses, and we are entitled to receive milestones plus a double-digit royalty on ex-U.S. sales. With that, let me turn the call back over to Michael.

Thank you, Keith. As you heard during our call, we have made tremendous progress over the past few months and are well-prepared for the transformational period ahead of us with the anticipated FDA approval and launch of our first two medicines. With the momentum we have built and our robust clinical development strategy designed to explore the full potential of Revumenib and Axatilimab, we are excited about the path ahead and the opportunity we have to make a major impact for patients. On Slide 14, you can see a recap of our upcoming anticipated milestones that we believe will continue to fuel our momentum and drive value. As always, I want to express my gratitude to the Syndax team and our partners for their hard work and dedication to our mission. Most importantly, I want to thank all of the patients, families, trial sites, and investigators who have participated in our trials and inspire us with their tenacity and commitment to finding new ways to improve the lives of patients with cancer. I'd also like to thank our committed long-term investors who continue to share in our vision and support our work building Syndax. With that, I would like to open the call for questions. Operator.

Our first question comes from Anupam Rama from JPMorgan. Your line is open, feel free to unmute.

Hi, thanks for taking the question. This is actually Malcolm Kuno on for Anupam. Can you remind us of the size and scope of the field force? And then what sort of medical education efforts will you have ongoing ahead of Axatilimab, Revumenib approval?

Thanks for the question, Malcolm. Let me turn it over to Steve to address it.

Yes, thanks, Malcolm, for the question. In terms of size, I think my comments in the opening was roughly 30 to 50. Sorry for the wide range. We haven't given an exact number, but it's adequate to cover the audience. We've got overlapping field teams. I mean, it's a complex treatment journey for patients. They've got treatment centers that have physicians and nursing staff and lab and pathology and formulary. So we've got different customer-facing teams to cover that; we will cover, I think I'd said, 98% of the opportunity. So it's in place. The field team is activating. I think your other question was around education and what are we doing. I'd say, for the field right now, as an organization, we're really trying to do two things. One of them is profiling accounts. I mentioned the complex treatment journey. We want to understand for any given institution that we call on how they do business, how they see patients, how they're treated. There's a ton for us to learn from understanding how they test for KMT2Ar, how those patients get highlighted for clinicians, how they like to deliver the drug, the role of nursing staff. So of the 2,000 accounts that I mentioned, we've already been to more than half of them. I also, I think I mentioned that we call in about 200 that are the priority accounts we've been to, probably at this point, 85% of them, and in some of them we've made multiple calls. So that's one thing we're doing and that's profiling accounts. And the goal is to, at the time of launch, know everything that we need to know in order to get patients on drug and treat it. The second piece is the education piece. There is a little bit of a lift here for Menin inhibition from a mechanism of disease standpoint. So that is something else that our field teams are delivering. We've also got a non-personal effort, really, to raise awareness, clearly not talking about the drug, at least from a commercial standpoint, but are raising awareness of the mechanism. We're the only one that's going to be out. The awareness level should be high by the time we get to launch, so between profiling, raising awareness, we’ll be in great shape once the drug gets approved to pull it through.

Great, thank you.

Our next question comes from Chris Shibutani from Goldman Sachs. Your line is now open.

Hi, this is Kevin Sterling for Chris. Thanks for taking my question. Just wanted to talk about the combination studies for Revumenib in the second half; you said you'd have data updates. Could you just highlight in bookend what those will be? I believe there's going to be an update from the SAVE trial. And then also for the BEAT AML trial. Can you talk about where you are with respect to establishing a recommended phase 2 dose there? And then what the rate-limiting steps are to start that pivotal trial by the end of the year? And then potentially how many doses you could bring forward into that trial? Thanks.

Thank you, Kevin. I'll address that. Regarding the BEAT AML trial, we're currently determining our recommended Phase 2 dose and have made significant progress. We presented data on both doses at EHA, and we are working on finalizing the expected number of patients for those doses. We will soon decide which dose will be the recommended Phase 2 dose, and we expect to start the pivotal trial by the end of this year. In the SAVE trial, led by Dr. Gus East at MD Anderson, we are examining relapse refractory patients who are being treated with Ven and COVI plus Revumenib. We shared data last year at ASH, and the investigators mentioned that there will be an updated presentation in the latter half of this year. We are looking forward to more patient data and additional follow-up, as the previous data was promising.

Great. Thank you.

The next question is from the line of Phil Nadeau from TD Cowen. Your line is now open.

Hi, Tim. This is Ernie Rodriguez for Phil. Thanks for taking our questions. I have two quick ones. The first one is, given the overlap in the target treatment centers between Revumenib and Axatilimab and all the prep work, commercial prep work that you've been doing, do you see any benefit to the now sort of like delay or longer time between the two launches? Can you see perhaps that maybe any benefit or any learnings that you can use to later accelerate the launch in KMT2A relative to what your internal estimates were? And then the second question is for the Intercept trial of Revumenib in monotherapy in the maintenance setting. I believe that trial has been ongoing for a while. I was wondering if there's any updates there, when could we see data from that trial? Thanks.

Great. Yes. Thanks for the questions. First, I'll ask Neil to address the trial question that you asked, and then Steve will address your commercial question.

Thanks. I think you're asking about the Intercept trial. So you're right, the Intercept trial has been ongoing for some time. The trial is progressing well. As you are also not aware, it is a third-party trial, and therefore, we don't control disclosure of data. But our understanding is that recruitment is going relatively well, and we expect that the investigators will present data at a medical meeting in the future. But we don't have an exact timing on that. With that, I'll pass over to Steve for your first question, actually.

Yes, to clarify, the first question was whether there is an advantage to having extra time, especially considering the overlap of the two compounds. Based on experience, it has always been the case that during the prelaunch period, no one wishes they had less time before a product approval—it's always about wanting more time. We now have more time with Revumenib than we initially expected. The activities I've mentioned will allow us to effectively utilize all the profiling and work on disease awareness as we work toward approval. The 2,000 accounts I referred to are ones we will likely visit, if not most of them, multiple times. This extended time will be beneficial. Additionally, there is significant overlap with the Axatilimab opportunity. While I didn't specify the number of treatment centers for chronic GVHD, we are essentially covering all of them by addressing the Revumenib opportunities. This involves 2,000 centers, both academic and community, for AML and Revumenib, compared to under 200 for transplant to support Axatilimab. We are already engaged with those as well. There is considerable connectivity between hematology and transplant, and Revumenib offers advantages as patients transition to our transplant and possibly continue treatment. We strategically view both drugs as highly aligned with our organizational goals. Since we share the same call points, we can effectively pursue both efforts. We will make the most of the time we have until either product reaches the market.

Thank you. Got it. That's helpful.

Our next question comes from the line of Peter Lawson from Barclays. Your line is now open.

Hi, good afternoon. This is Alex on for Peter from Barclays. Thanks for taking our questions. Just a quick clarification for me on the BEAT AML study. Do we see more data from this study later this year? And then a separate question is, could we see initial Phase 1 data from your 7 plus 3 combination in 2024?

Hi, Alex, thanks for the question. For the BEAT AML trial, this is not our trial. We are working closely with the sponsor, and the last update was at EHA, which was quite comprehensive. We do not know when the next update will be. It might come in the second half of this year at one of the medical meetings, but we don't have complete information on that yet, so please stay tuned. Regarding the 7 plus 3 phase one that we've started, we haven't provided guidance on when the initial data will be available, so please stay tuned for that as well. I wouldn't expect it to be available in 2024; it will likely come in 2025.

Okay, great. And just, if I may, a quick follow-up. Do you have to enroll sort of adverse risk patients here initially, or what types of patients are being enrolled in the phase 1? Thank you.

Yes, I don't think we've actually talked about the exact type of patients that we're enrolling. That's right. I think they're just newly diagnosed patients with the 7 plus 3 in combination.

Thank you. Our next question comes from the line of Brad Canino from Stifel. Your line is now open.

Thank you. This is Brad. I think it would be good to clear up some of the sequence around the Revumenib review. I think a lot of us presumed that with RTOR and the close FDA collaboration that that provides, plus your proactive commercial approach, that you had really good visibility about what you needed to get this across the line either at or well before the PDUFA. So can you help us understand a bit of what happened here?

Thank you, Brad. Earlier this week, we connected with many of you following the news. Unfortunately, we received several requests for information, part of an ongoing process under RTOR since we submitted our NDA last year. The most recent requests required us to provide considerable information to the agency. As of late last Friday, they indicated that they would need more time to review the supplemental information, leading to a three-month delay. We have been very collaborative with the agency over the past months and submitted information we believed could be reviewed within the original PDUFA timeline. While we were surprised by the extension, that decision is ultimately theirs. The information they requested was not part of our NDA submission, but rather new clinical information that we provided. The unfortunate aspect is that we were informed of this late in the review cycle, after our mid-cycle and late-cycle reviews, which had gone smoothly. We remain confident that our submission and correspondence with the agency were solid. Despite this setback, we are optimistic about the drug's approval timeline in December, and we are well positioned to launch it before the year's end.

Yes. And maybe just to follow on that, because I think many of us are now looking at a situation where there's a potential for heightened asymmetry of information. You've got the FDA potentially looking at data that we haven't been able to vet, I guess, what assurance can you give that the overall profile that we know publicly from Revumenib is consistent and that prior data cut remains reliable? Thank you.

Yes, thanks, Brad. Look, I think the information, and we don't get into the specifics of any one request for information and what's being asked of us in an ongoing review. But what I can say is that the late-cycle review we did learned that there's going to be no Advisory Committee meetings for the product, and they assured us no REMS program for that would be required as well. This is not manufacturing information that they've looked for. It's a clinical package that is, in our minds, completely consistent and supportive of approval. This is not information that changes the profile of the risk-benefit at all. And so we feel actually it's even more robust of a package than as previously worked on. It was basically what the agency had asked for and they asked for supplemental information. So we feel like it doesn't change anything at all having to do with the profile or the risk-benefit. And for that reason, that's why we're so confident that the drug will not only get approved, but it'll get approved on the timeline as proposed. So I think that's as detailed as I could get for you, Brad.

The next question comes from the line of Michael Schmidt from Guggenheim. Please go ahead.

Hi guys, thanks for taking my question. Maybe just a quick follow-up. So given that the Revumenib NDA obviously is still under RTOR review, and with the extended PDUFA date till the end of September now giving ample time for the FDA, just wondering what your view is on the potential for an approval to come ahead of that extended PDUFA date. Is that still on the table, any opinion? And then I had an unrelated follow-up.

Yes, Michael, I appreciate your question. It's not uncommon for extensions to occur, and we've seen a few of our RTOR products, like Rezurock, approved earlier than their extended timelines. So, it's possible for RTOR products to get extended and eventually approved. Many products under priority review experience similar outcomes. Typically, they are approved around their extended PDUFA date. While we expect to receive approval on or before that date, it's challenging to predict how closely that will align with the extended date itself. Our expectation is that it will occur around the specified date.

Super helpful, thanks. And then unrelated follow-up. Just sort of thinking about the upcoming registration data in NPM1 patients later this year, perhaps relative to KMT2Ar, how should we think about the transplant dynamics in the NPM1 subset? And related to that, what's a good modeling assumption for durational therapy for that market subset relative to KMT2Ar, thanks so much.

Yes, thank you for the question. Our perspective on NPM1 has consistently been that the data from the Phase 1 trial aligns closely with what we've observed in KMT2A, showing consistency across all measures between the datasets. This includes findings related to transplantation. While patients in the NPM1 group tend to be older compared to those with KMT2A, a significant number of these patients have also undergone transplantation. Although physicians may feel more urgency to transplant KMT2A patients, it does not stop them from considering transplantation for NPM1 patients if they are healthy enough and have cleared their tumors. We have seen this trend in both NPM1 and KMT2A populations. Therefore, we believe the modeling assumptions should be quite similar regarding the proportion of patients proceeding to transplantation and potentially returning to treatment post-transplant, despite the slightly older demographic in NPM1. This is based on the data we've collected from the Phase 1 trial and our current pivotal trial for KMT2A.

Great. Thank you.

Thanks, Michael.

Our next question comes from the line of Kelly Shi from Jefferies. Your line is now open.

Hi, this is Claire on Kelly. Thanks for taking our question. So, now that you will likely have pivotal data readout in NPM1 that had approval in KMT2A wonder, how would that possibly change your discussion with the NCCN committee for the guideline inclusion and maybe, one step forward also, what will be the conversation with payers going to be like upon this update as well? Thank you.

Yes, thank you for the question. We believe that we will have the NPM1 data from our pivotal trial before our KMT2A approval. They will be closely timed, but NPM1 data will come first. Our main goal is to publish that data as quickly as possible. Once the KMT2A drug is approved, we can start pursuing its inclusion in guidelines for NPM1. There is a sense of urgency to ensure we have a drug available in the market. Additionally, there's an NPM1 indication that is progressing rapidly through the sNDA process and may be included in guidelines before its approval. We will be active not just in getting the drug approved but also in advancing guidelines through publications and discussions with thought leaders who can help incorporate new drugs into guidelines. Now, I'll hand it over to Steve to address the other questions.

I think part two is what is the impact on payers of NPM1. In my opening comments, I talked about our activity with payers, which has been extensive. We'll have talked to payers that cover 90% of managed care lives in both commercial and Part D. I think payers, they recognize the unmet need in KMT2A, and they recognize it in NPM1. They like what they've seen with Revumenib. And given the price point in the space of roughly $27,000 to $32,000 a month, we believe we'll be at a slight premium to those agents. It's an obvious connection between NCCN guidelines and payers. Payers like to see what's in the public domain. They want to see data published, they want to see the guidelines clearly. The entry point is KMT2A. That's where we'll set price. I think payers want to service patients. They'll produce some hurdles and obstacles up front, and barriers which they always deal with products like this. We've got fantastic specialty pharmacy partners and distributors, and a patient portal when needed to usher patients through the early days of a launch when products are not yet on formulary. So we understand the medical exception process as well as our preferred pharmacy partners, as well as treaters and institutions. So we think either way we'll be able to set the right price and we'll be able to get patients on drug with some challenge. But we'll get there, and we're prepared to do it.

Thank you. That was very helpful.

Thanks, Claire.

Next question comes from Yigal Nochomovitz from Citi. Your line is now open.

Hi, this is Ashiq Mubarack filling in for Yigal. I appreciate you taking my questions. I wanted to ask about Axatilimab. It seems everything is on schedule with the PDUFA coming up soon. Could you provide any updates on the BLA process? Have you started label negotiations? Was there any information from a mid-cycle review? Any confirmation that the BLA is progressing would be helpful. Thank you.

Yes, Ashiq. Thank you for your question. We do not provide details on specific parts of our negotiations or discussions with the agency. The drug is currently under priority review. As we've mentioned before, everything is progressing positively. We expect the drug to be approved around the PDUFA date at the end of August. Nothing encountered during the review process has changed our perspective. While I won't comment on whether we are in label discussions, we are very confident that the drug will receive approval on schedule.

Okay. Maybe one follow-up on that then. Should we sort of expect the commercial launch to take place maybe immediately after a potential approval of Axatilimab? Or is there a reason to sort of think there might be a little bit of a lag, maybe waiting for Revumenib, so there's some synergy with that commercial launch as well? Thanks.

Right. So, no, thanks for the follow-up, Ashiq. We said that the launch is expected in the fourth quarter, so that's our guidance. We're working with our partner to get ready to do that, and we'll launch the drug when it's ready.

Our next question comes from the line of Kalpit Patel from B. Riley. Your line is now open.

Yes. Hi, good afternoon, and thanks for taking the question. Maybe one for Revumenib. Is there anything that you've learned from the KMT2Ar regulatory filing here that could be beneficial for the NPM1 filing and help streamline that? I know the timeline says first half '25 instead of maybe first quarter '25. Is there a reason for that? And then I have a follow-up.

Yes. Thanks, Kal. Let me turn it over to Neil to maybe take a crack at that.

Yes, thank you for the question. The simple answer is yes. We have gained significant insights from the process, particularly in distinguishing between the NDA and the sNDA. We handled much of the groundwork in the NDA, making any subsequent supplementary applications much easier. We are excited to receive the NPM1 data in the fourth quarter and will ensure that we submit that data as quickly as possible. I think I might have missed part of your question. Did I cover everything, or is there something else you wanted to ask?

Yes. It mentions the first half of '25 instead of the first quarter of '25 for filing for the NPM1 cohort.

Yes, we haven't provided specific guidance yet, but you can be sure that we will be working hard on it. I will now pass you back to Michael.

Kal, your second question?

Yes. Was there new information requested by the FDA? Was any part of the NPM1 cohort data set sent to the FDA for this update?

No, Kalpit, I would just focus on the KMT2A submission. That's what we're currently working on with the FDA. The NPM1 data is not ready yet, as we haven't completed the trial. Once that trial is finished and the data is available, we will publish it, expected in the fourth quarter. So, our current emphasis with the agency is on KMT2A.

Thank you. Our next question comes from the line of Justin Zelin from BTIG. Your line is now open.

Thanks for taking our question. Michael, I'd like to clarify regarding your confidence on the Revumenib approval by the end of the year. Should we continue to expect a traditional approval here, or could there be a scenario in the review cycle where Revumenib could be approved under an accelerated approval basis?

Justin, thank you for your question. I want to make it clear that we should not assume the approval will be anything other than full approval. All previously approved drugs for AML as monotherapy-targeted therapies have followed the same exact process, and we have not discussed any alternative paths with the agency. There is not an accelerated approval pathway we are pursuing here, so I wouldn't expect any changes in that regard. Furthermore, we have a high level of confidence that the delay will be just three months and will not affect our filing process or the likelihood of approval.

Great. Thanks for clarifying and taking our question.

The next question comes from the line of Jason Zemansky from Bank of America. Your line is open.

Hi, good afternoon. This is Cameron Bozdog on for Jason. Congrats on the progress, and thanks so much for taking our question. So, looking ahead to the potential near-term launch of Axatilimab, can you maybe comment on your internal market analyses and what you've been hearing from prescribers? I mean, do you expect uptake, at least initially, to be largely driven by academic prescribers centered at transplant centers versus community docs, especially when you think about the route to administration? Thank you.

Great. Thanks for the question. I'm going to turn it over to Steve to address it.

Thanks for the question, Cam. To start, the audience is quite small, consisting mostly of high-level experts in transplantation. From the treatment center perspective, 10% of the centers are handling under 200 patients, so that drives the situation. In terms of academic versus community influence, the largest centers will mainly lead this effort. At launch, there will be some awareness beyond that group, and within those 200 centers, about 35 centers account for half the patients in the country. While it may not be the smallest physician audience, it is among the smallest, and it represents a close-knit community. Speaking of market opportunity, there is significant business potential as there is a lot of unmet need and dissatisfaction in the current treatment landscape for GVHD. Patients are seeking more options, as the disease can be quite challenging. Initially, there may be some early uptake from patients who have been waiting for something new. Although the number may not be large, there is still a demand. Therefore, we anticipate a noticeable initial influx, and the market is ready and will continue to prepare. I believe both physicians and patients will respond positively.

And our final question comes from the line of George Farmer from Scotiabank. Your line is open.

Hi, this is Chloe on for George. Can you hear me okay?

I hear you, Chloe. Thank you.

Yes. So two from us. So, based on your initial data package for Revumenib, so you said that FDA did its thing and ODAC was necessary. You still believe now to be the case. So how confident are you that the additional information is submitted that prompted the proof extension will not be the subject of an ODAC review in the next six months? And the second question is, Michael, you mentioned BD in your prepared remarks, so just curious what types of BD deals you had in mind and examples of areas of interest or types of assets. Your eyes at the moment, both as a buyer or even a target, and if you could maybe put it in context to give the Incyte relationship for us and tell us kind of how you see that evolving over time.

Thank you for the question, Chloe. First, regarding ODAC, I am quite confident that an ODAC will not be necessary. The agency has indicated this on several occasions. The data we submitted is clearly supportive of approval and enhances the overall package we provided. Therefore, based on our understanding and what we've heard from the agency, there doesn't seem to be any risk of an ODAC from what we know. I feel very confident about this. As for business development, it relates to how we can expand our pipeline while continuing to excel at Syndax, particularly through the in-licensing or acquisition of new molecules to enhance our offerings. We have mentioned before and continue to focus on adding early-stage molecules in the targeted therapy area of oncology. However, we do not discuss specific mechanisms or the status of these discussions until deals are finalized, at which point we will share that information publicly. For now, we are actively seeking opportunities and feel optimistic about our potential. However, it's challenging to predict business development transactions until they are completed. We are primarily looking at earlier projects, rather than late-stage ones, in alignment with the other exciting developments we have underway for Axatilimab and Revumenib. Our approach is balanced, and we are fully engaged in this strategy.

Thanks for the update. Regarding the partnership with Incyte, do you have any insights on how you envision its development in the future?

Our partnership with Incyte has been beneficial since we established it in 2021, and they have been excellent collaborators. As Steve mentioned, we are eager to get the product approved and launched, and to broaden the use of Axatilimab for various indications earlier in the treatment process for GVHD. We are also exploring IPF. This is a global partnership with Incyte that has been progressing well, and we believe it will continue to grow in the way we initially envisioned. We are very pleased with this relationship.

Got it. Thank you.

Thank you, Chloe.

This concludes the question-and-answer session. I'll now turn the floor over to Mr. Michael Metzger for any additional comments or closing remarks.

Yes. Thank you, all. We appreciate you all tuning in today to discuss the progress we have made and the exciting milestones ahead for the Company. We look forward to seeing you at our planned investor events, including the upcoming BTIG Conference in August. And with that, wish you a good day. Thank you so much.